수의용 통증 관리 시장 - 세계 예측(2026-2032년)

The Veterinary Pain Management Market is projected to grow by USD 4.47 billion at a CAGR of 10.28% by 2032.

Veterinary Pain Management Moves From Supportive Care to Evidence-Based Clinical Priority

Veterinary pain management is becoming a core pillar of modern animal healthcare as clinicians, pet owners, livestock producers, and regulators place greater emphasis on animal welfare, evidence-based analgesia, and improved recovery outcomes. Pain in companion animals, equine patients, and production animals is now recognized as a complex clinical condition that requires timely assessment, multimodal treatment, and continuous monitoring across surgical, orthopedic, dental, oncologic, neurologic, and chronic disease settings. The field includes nonsteroidal anti-inflammatory drugs, opioids where permitted, local anesthetics, alpha-2 agonists, gabapentinoids, monoclonal antibodies, nutraceutical adjuncts, regenerative therapies, physical rehabilitation, acupuncture, laser therapy, and digital pain assessment tools.

Demand is being shaped by rising pet humanization, longer animal lifespans, higher prevalence of osteoarthritis and chronic mobility disorders, increased adoption of companion animal insurance in select countries, and stronger expectations for perioperative analgesia. In food-producing animals, welfare certification schemes, antimicrobial stewardship programs, and productivity considerations are encouraging better recognition and treatment of pain associated with lameness, castration, dehorning, calving, transport injury, and infectious or inflammatory conditions. Across veterinary practices, the strategic priority is shifting from episodic pain relief to integrated pain protocols that combine diagnostics, pharmacology, behavior assessment, rehabilitation, and owner education.

Transformative Shifts Toward Multimodal, Preventive, and Welfare-Driven Pain Care

The veterinary pain management landscape is undergoing a significant transformation as the profession moves toward multimodal analgesia, individualized dosing, and objective pain scoring. Traditional reliance on a narrow set of anti-inflammatory or opioid-based interventions is giving way to layered protocols that balance efficacy, safety, species-specific metabolism, comorbidities, and duration of pain. Companion animal clinics are increasingly using structured pain scales, mobility questionnaires, orthopedic screening, and postoperative monitoring to guide treatment selection, while referral hospitals are expanding anesthetic and rehabilitation capabilities for complex cases.

Regulatory and social pressures are also reshaping the field. Restrictions and oversight related to controlled substances are encouraging clinicians to optimize non-opioid pathways, regional anesthesia, local blocks, and long-acting therapeutics. At the same time, growing consumer awareness of animal discomfort has increased demand for chronic pain management in aging dogs, cats, and horses. In livestock systems, welfare standards and retail supply-chain requirements are reinforcing the importance of analgesia during routine husbandry procedures. Digital health platforms, wearable activity monitors, tele-triage tools, and electronic medical records are further enabling continuous assessment rather than one-time clinical observation. These shifts are creating a more protocol-driven, outcome-oriented environment in which pain recognition, documentation, and follow-up are central to quality veterinary care.

Cumulative Impact of Artificial Intelligence on Pain Detection and Clinical Decision Support

Artificial intelligence is beginning to influence veterinary pain management by improving how pain is detected, classified, monitored, and documented. Because animals often mask discomfort and clinical signs vary by species, AI-enabled image analysis, gait evaluation, facial expression recognition, posture tracking, and activity monitoring can support earlier identification of pain-related behavior. These technologies are particularly relevant in osteoarthritis, post-surgical recovery, equine lameness, and herd-level welfare monitoring, where subtle changes in movement, feeding, resting, or social behavior may indicate worsening pain.

AI also has a cumulative impact on clinical decision support. Integrated with electronic health records, diagnostic imaging, laboratory data, and owner-reported outcomes, AI tools can help standardize pain scoring, flag treatment gaps, and support follow-up scheduling. In livestock operations, machine vision and sensor-based analytics can assist in detecting lameness, injury, or abnormal behavior at scale, improving both welfare and operational efficiency. However, adoption depends on validation, explainability, cybersecurity, data quality, clinician oversight, and alignment with veterinary regulatory standards. AI is not replacing clinical judgment; it is strengthening pain recognition and enabling more consistent, data-informed intervention across diverse animal populations.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is advancing rapidly in veterinary pain management due to expanding companion animal ownership, rising veterinary service utilization, and increasing attention to livestock welfare across diverse production systems. Urban pet ownership in China, India, Japan, South Korea, and Australia is supporting higher demand for orthopedic care, geriatric pain treatment, dental procedures, and rehabilitation, while large livestock populations across the region create ongoing need for practical analgesic protocols in cattle, swine, poultry, and small ruminants. Variation in veterinary infrastructure remains significant, with highly specialized referral care concentrated in mature urban markets and access gaps persisting in rural and emerging economies.

North America remains one of the most protocol-driven regions for veterinary pain management, supported by advanced companion animal care, broad availability of specialty practices, established animal welfare guidelines, and strong adoption of diagnostic imaging, rehabilitation, and chronic disease management. The United States and Canada show high clinical emphasis on perioperative analgesia, osteoarthritis management, dental pain control, and multimodal care, while Mexico is seeing growing modernization of companion animal clinics alongside livestock-focused welfare needs.

Latin America combines expanding pet healthcare demand with a strong production-animal base. Brazil and Mexico are key contributors to regional veterinary service development, with pain management priorities spanning companion animal surgery, equine care, cattle handling, and herd health. Access, affordability, and product availability vary considerably across markets, making education, practical dosing guidance, and scalable welfare protocols essential.

Europe is shaped by rigorous animal welfare expectations, mature veterinary education, and strong scrutiny of antimicrobial and controlled-substance use. Pain management practices emphasize documentation, preventive analgesia, rehabilitation, and compliance with welfare regulations across companion and farm animals. The region's clinical environment favors validated pain scales, responsible prescribing, and non-opioid adjunctive strategies.

The Middle East is experiencing growth in companion animal care, equine medicine, and veterinary infrastructure, particularly in urban centers and countries investing in advanced animal health services. Pain management needs are influenced by equine sports medicine, small animal surgery, and food-animal welfare modernization. Africa presents a heterogeneous landscape, with major pain management needs in livestock health, working animals, wildlife medicine, and expanding urban companion animal practice. Resource constraints, veterinary access, and supply-chain reliability remain central challenges, but welfare education and practical analgesia protocols are gaining importance.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries are seeing stronger interest in veterinary pain management as urbanization, middle-class pet ownership, and food-animal production intensify across Southeast Asia. Companion animal clinics in major cities are adopting more structured perioperative and chronic pain practices, while livestock sectors require cost-effective analgesic approaches that can be implemented within large-scale and smallholder systems. Training, product access, and harmonized standards are important enablers across the group.

The GCC is characterized by rising investment in companion animal services, equine care, falconry-related veterinary expertise, and modern livestock systems. Pain management adoption is supported by advanced clinics in major urban areas and demand for high-quality surgical, orthopedic, and sports medicine services. The European Union places strong emphasis on animal welfare, pharmacovigilance, responsible medicine use, and standardized veterinary practice. EU policy frameworks and professional guidelines encourage documented pain assessment, humane management of farm procedures, and careful control of analgesic use in food-producing animals.

BRICS economies represent a broad mix of high-growth companion animal markets, large livestock populations, and expanding veterinary infrastructure. China, India, Brazil, Russia, and South Africa share significant needs for scalable pain management across urban pet care and production-animal systems, although access and regulatory environments differ markedly. The G7 group reflects mature veterinary systems with extensive clinical specialization, strong research capacity, and widespread use of evidence-based protocols in companion animal surgery, osteoarthritis, oncology, dentistry, and rehabilitation. NATO countries overlap substantially with developed veterinary markets in North America and Europe, where defense-related working animals, service dogs, equine programs, and public-sector veterinary standards add further relevance to pain recognition, trauma care, and rehabilitation.

Key Country Insights Across Major Veterinary Pain Management Markets

The United States leads in advanced veterinary pain management practices through widespread specialty care, structured anesthesia protocols, rehabilitation services, and strong demand for chronic pain treatment in aging companion animals. Canada shows similar emphasis on welfare, postoperative analgesia, and responsible prescribing, with geographic access challenges in remote areas. Mexico is modernizing companion animal care in urban centers while maintaining significant livestock-related analgesia needs. Brazil combines a large companion animal population with major cattle, poultry, and swine industries, making both pet pain care and production-animal welfare important. The United Kingdom has a mature veterinary profession, high pet ownership engagement, and strong welfare expectations that support documented pain assessment and multimodal analgesia.

Germany, France, Italy, and Spain show advanced European approaches to animal welfare, preventive pain control, and responsible medicine use across companion and farm animals. Germany is notable for rigorous veterinary standards and strong clinical infrastructure, while France emphasizes both companion animal medicine and livestock welfare. Italy and Spain are important markets for small animal surgery, equine medicine, and geriatric pet care. Russia presents a mixed environment, with advanced veterinary services in major cities and uneven access across wider regions. China is experiencing rapid expansion in urban pet healthcare, with increasing demand for orthopedic, dental, and chronic pain solutions, alongside large-scale livestock health needs. India has a dual profile: accelerating companion animal care in metropolitan areas and extensive requirements for livestock, working animal, and rural veterinary pain management.

Japan has a highly developed companion animal care environment, supported by an aging pet population and demand for chronic disease and mobility management. Australia combines advanced small animal medicine with strong livestock and equine sectors, where welfare-driven pain protocols are increasingly important. South Korea is expanding veterinary specialization, pet insurance awareness, and advanced companion animal services, supporting broader adoption of pain assessment, surgical analgesia, and long-term mobility care.

Actionable Recommendations for Veterinary Pain Management Industry Leaders

Industry leaders should prioritize evidence-based, species-specific pain management strategies that align with clinical guidelines, regulatory expectations, and real-world veterinary workflows. Product development should focus on safer long-duration analgesics, non-opioid alternatives, improved formulations for cats and other species with unique metabolic considerations, and solutions suitable for both clinic-based and field-based use. Education remains a critical differentiator: veterinarians, technicians, livestock handlers, and pet owners need practical guidance on pain recognition, dosing adherence, monitoring, adverse-event reporting, and follow-up care.

Organizations should invest in multimodal care ecosystems that integrate pharmaceuticals, diagnostics, rehabilitation, digital monitoring, and outcome tracking. Partnerships with veterinary educators, welfare bodies, and professional associations can strengthen adoption of validated pain scales and standardized protocols. For emerging markets, affordability, cold-chain resilience, packaging flexibility, and local training can improve access. For mature markets, differentiation should focus on clinical evidence, safety profiles, ease of administration, compliance support, and digital integration. Leaders should also prepare for the growing role of AI by ensuring data integrity, ethical use, validation, and clinician-centered design.

Research Methodology Based on Verified Clinical, Regulatory, and Welfare Evidence

The research methodology for analyzing veterinary pain management should combine secondary research, expert validation, and structured data triangulation. Reliable inputs include peer-reviewed veterinary journals, regulatory guidance, veterinary medical association resources, animal welfare standards, pharmacovigilance documentation, clinical practice guidelines, public health and agriculture sources, and scientific literature on analgesia, anesthesia, osteoarthritis, rehabilitation, and species-specific pain behavior. Regional and country-level interpretation should consider veterinary infrastructure, animal demographics, livestock systems, medicine access, regulatory controls, and welfare requirements.

Primary validation should include perspectives from veterinarians, anesthesiologists, surgeons, rehabilitation specialists, livestock health experts, animal welfare professionals, distributors, and regulatory specialists. Insights should be assessed through qualitative consistency checks rather than unsupported numerical assumptions. Because this executive summary avoids market sizing, market share, and forecasting, the emphasis is placed on verified clinical trends, adoption drivers, regulatory context, technology impact, and strategic implications. Data triangulation across scientific evidence, practitioner experience, and policy frameworks helps ensure balanced, decision-ready conclusions.

Conclusion: Veterinary Pain Management Advances Through Welfare, Evidence, and Digital Innovation

Veterinary pain management is evolving into an integrated, data-informed discipline that supports animal welfare, clinical quality, and long-term care outcomes. The strongest momentum is coming from multimodal analgesia, chronic pain recognition, geriatric pet care, livestock welfare requirements, and the gradual introduction of AI-enabled assessment tools. Regional differences remain important: mature markets are advancing through specialization, digital integration, and standardized protocols, while emerging markets are focused on access, affordability, training, and scalable welfare practices.

For industry participants, success will depend on aligning innovation with veterinary realities: species-specific safety, ease of administration, regulatory compliance, measurable outcomes, and education for both professionals and animal owners. As expectations for humane and evidence-based care continue to rise, veterinary pain management will remain a critical area of clinical advancement across companion animals, equine medicine, livestock production, working animals, and wildlife care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Veterinary Pain Management Market, by Product Type

• 7.1. Introduction
• 7.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 7.2.1. Carprofen
  • 7.2.2. Flunixin
  • 7.2.3. Meloxicam
  • 7.2.4. Robenacoxib
• 7.3. Opioids
  • 7.3.1. Morphine
  • 7.3.2. Buprenorphine
  • 7.3.3. Fentanyl
• 7.4. Local Anesthetics
  • 7.4.1. Lidocaine
  • 7.4.2. Bupivacaine
  • 7.4.3. Ropivacaine

8. Veterinary Pain Management Market, by Animal Type

• 8.1. Introduction
• 8.2. Cats
• 8.3. Dogs
• 8.4. Equine
• 8.5. Livestock

9. Veterinary Pain Management Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Injectable
  • 9.2.1. Intramuscular
  • 9.2.2. Intravenous
  • 9.2.3. Subcutaneous
• 9.3. Oral
• 9.4. Topical
  • 9.4.1. Gels
  • 9.4.2. Patches
  • 9.4.3. Sprays
• 9.5. Transdermal

10. Veterinary Pain Management Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Direct Distribution
• 10.3. Hospital Pharmacies
• 10.4. Online Pharmacies
• 10.5. Retail Pharmacies

11. Veterinary Pain Management Market, by End User

• 11.1. Introduction
• 11.2. Veterinary Hospitals
• 11.3. Academic & Research Institutes
• 11.4. Livestock Farms
• 11.5. Veterinary Clinics
• 11.6. Animal Rehabilitation Centers

12. Veterinary Pain Management Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Veterinary Pain Management Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Veterinary Pain Management Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Bimeda Holdings PLC
• 16.2. Boehringer Ingelheim International GmbH
• 16.3. Ceva Sante Animale S.A.
• 16.4. Dechra Pharmaceuticals PLC
• 16.5. Elanco Animal Health Incorporated
• 16.6. Kyoritsu Seiyaku Corporation
• 16.7. Laboratorios Calier, S.A.
• 16.8. Merck & Co., Inc.
• 16.9. Neogen Corporation
• 16.10. Nextmune Holding B.V.
• 16.11. Norbrook Laboratories Limited
• 16.12. Orion Corporation
• 16.13. Parnell Pharmaceuticals Holdings Ltd.
• 16.14. PetVivo Holdings, Inc.
• 16.15. Phibro Animal Health Corporation
• 16.16. SeQuent Scientific Limited
• 16.17. Vetbiolix SAS
• 16.18. Vetcare Oy
• 16.19. Vetoquinol S.A.
• 16.20. VETRISCIENCE Laboratories
• 16.21. Virbac S.A.
• 16.22. Zoetis Inc.
• 16.23. Zomedica Corp.